Molika Ashford from GenomeWeb and 360Dx recently interviewed our CEO, Fredrik Wetterhall, discussing how AI-based prognostic analyses are emerging as a viable alternative to genomic tests. And how this shift is already underway, with Stratipath Breast gaining traction in clinical settings and backed by growing scientific evidence.
“The customers we have, they’re using our test as an alternative to molecular assays … and I think the main benefit with AI-based precision diagnostics is that they can get results in minutes instead of weeks,” says Fredrik Wetterhall in the interview.
”Although the company is still early in its clinical foray, Wetterhall said that it believes it can also serve markets where molecular testing has proliferated, including the UK and US, by offering a more rapid option.”
